A comparison of kinetics of paraprotein clearance after infusional chemotherapy versus high-dose melphalan in previously untreated patients with IgG multiple myeloma.

被引：0
|
作者：
Sirohi, B
Powles, R
Sumpter, K
Kulkarni, S
Singhal, S
Bhagwati, N
Horton, C
Saso, R
Mehta, J
Treleaven, J
机构：
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4631
引用
收藏
页码：314B / 314B
页数：1
相关论文
共 50 条
  • [21] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal, S
    Powles, R
    Sirohi, B
    Treleaven, J
    Mehta, J
    BLOOD, 2001, 98 (11) : 816A - 816A
  • [22] Variation in melphalan dosing in myeloma patients undergoing high-dose chemotherapy and autotransplantation
    Mehta, J.
    Carson, K. R.
    Trifilio, S.
    Vickrey, E.
    Allen, S.
    Singhal, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Impaired PBPC collection in patients with myeloma after high-dose melphalan
    Jansen, J
    Thompson, JM
    Dugan, MJ
    Wiemann, MC
    Hanks, S
    Greenspan, AR
    Akard, LP
    CYTOTHERAPY, 2004, 6 (05) : 498 - 504
  • [24] Single high-dose chemoradiotherapy versus tandem high dose melphalan followed by Auto-SCT for advanced multiple myeloma. Preliminary analysissis.
    Einsele, H
    Liebisch, P
    Bargou, R
    Meisner, C
    Metzner, B
    Wandt, H
    Wolf, HH
    Sezer, O
    Casper, J
    Pfreundschuh, M
    Maschmeyer, G
    Straka, C
    Truemper, L
    Kroeger, N
    Mueller, P
    Hertenstein, B
    Frickhofen, N
    Coser, P
    Bamberg, M
    Hebart, H
    Kanz, L
    BLOOD, 2004, 104 (11) : 156A - 156A
  • [25] Comparison of high dose melphalan and a more intensive regimen of thiotepa, busulfan and cyclophosphamide in multiple myeloma.
    Anagnostopoulos, A
    Aleman, A
    Ayers, D
    Williams, P
    Xin, L
    Donato, M
    Alexanian, R
    Champlin, R
    Giralt, S
    BLOOD, 2002, 100 (11) : 436A - 436A
  • [26] Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma.
    Knop, Stefan
    Hebart, Holger
    Kunzmann, Volker
    Angermund, Ralf
    Einsele, Hermann
    BLOOD, 2006, 108 (11) : 364B - 364B
  • [27] High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Monge, Jorge
    Niesvizky, Ruben
    Hsu, Jing Mei
    Shore, Tsiporah
    Van Besien, Koen
    Pearse, Roger
    Mark, Tomer
    Jayabalan, David
    Mayer, Sebastian Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Cangini, D.
    Cerchione, C.
    Giannini, M. B.
    Di Battista, V.
    Frabetti, F.
    Petracci, E.
    Ronconi, S.
    Martinelli, G.
    HAEMATOLOGICA, 2019, 104 : 163 - 163
  • [29] Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    Anagnostopoulos, A
    Aleman, A
    Ayers, G
    Donato, M
    Champlin, R
    Weber, D
    Alexanian, R
    Giralt, S
    CANCER, 2004, 100 (12) : 2607 - 2612
  • [30] Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma.
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Davis, Marilyn S.
    Mendoza, Floralyn L.
    Hosing, Chitra
    Couriel, Daniel R.
    De Lima, Marcos
    Kebriaei, Partow
    Weber, Donna M.
    Wang, Michael
    Alousi, Arnin M.
    Matthes, Steven G.
    Jones, Roy B.
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2006, 108 (11) : 881A - 881A
12345